GSK to buy US cancer treatment firm Nuvalent for $10.6bn

The Guardian World

British drugmaker’s new chief executive Luke Miels announces one of its biggest deals

Business live – latest updates

GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.

The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer.
Continue reading...

전문 보기

GSK to buy US cancer treatment firm Nuvalent for $10.6bn

관련 뉴스

'world' 카테고리 뉴스

Gatchalian orders remote work amid Senate threat; contradicts Cayetano

Palace hands-off on graft claims vs DOH chief Herbosa, Domingo

Senate invites parties, sets June 18 impeachment pre-trial conference

The Guardian의 다른 기사

White House urges UK not to ban social media for under-16s

James Blood Ulmer, adventurous US guitarist and vocalist, dies aged 86

KLM apologises after Paralympian denied onboard wheelchair on 11-hour flight